Trial Profile

Comparison of pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Aug 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Bristol-Myers Squibb

Most Recent Events

02 Aug 2011 New trial record
23 Jul 2011 Results reported in an abstract at 23rd Congress of the International Society on Thrombosis and Haemostasis.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com